Company registration number 09053005 (England and Wales)
THE BIONIC EYE LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025
PAGES FOR FILING WITH REGISTRAR
THE BIONIC EYE LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
THE BIONIC EYE LIMITED
BALANCE SHEET
AS AT 30 NOVEMBER 2025
30 November 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
13,715
4,209
Current assets
Stocks
324,468
111,951
Debtors
4
38,709
32,516
Cash at bank and in hand
14,198
29,240
377,375
173,707
Creditors: amounts falling due within one year
5
(123,909)
(28,183)
Net current assets
253,466
145,524
Total assets less current liabilities
267,181
149,733
Provisions for liabilities
(3,422)
-
Net assets
263,759
149,733
Capital and reserves
Called up share capital
6
100
100
Capital redemption reserve
11
11
Profit and loss reserves
263,648
149,622
Total equity
263,759
149,733

For the financial year ended 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 17 April 2026
A J Eio
Director
Company registration number 09053005 (England and Wales)
THE BIONIC EYE LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 2 -
1
Accounting policies
Company information

The Bionic Eye Limited is a private company limited by shares incorporated in England and Wales. The registered office is 22 Wycombe End, Beaconsfield, Buckinghamshire, HP9 1NB.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is measured at the fair value of the consideration received or receivable for the rendering of services in the normal course of business, and is shown net of discounts and VAT.

Rendering of services

Revenue arises from the provision of data services for unmanned aerial vehicles. Revenue is recognised proportionally over the performance of the service contract, by reference to the stage of completion of the transaction at the end of the reporting period.

1.3
Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and machinery
25% straight line
Fixtures, fittings & equipment
25% straight line
Computer equipment
25% straight line
Motor vehicles

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

1.5
Financial instruments

The company has elected to apply the provisions of Section 11 ”Basic Financial Instruments” to all of its financial instruments.

 

Financial instruments are recognised in the company’s balance sheet when the company becomes party to the contractual provisions of the instrument.

THE BIONIC EYE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 3 -
Basic financial assets

Short term debtors are measured at transaction price less any provision for impairment. Loans receivable are measured initially at fair value, net of transaction costs and are subsequently carried at amortised costs using the effective interest method, less any provision for impairment.

Basic financial liabilities

Short term creditors are measured at transaction price. Other financial liabilities, including loans to other companies, are measured initially at fair value, net of transaction costs and are subsequently carried at amortised costs using the effective interest method.

1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.7
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

1.8
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.9
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

THE BIONIC EYE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 4 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
2
2
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 December 2024
48,367
Additions
11,451
At 30 November 2025
59,818
Depreciation and impairment
At 1 December 2024
44,158
Depreciation charged in the year
1,945
At 30 November 2025
46,103
Carrying amount
At 30 November 2025
13,715
At 30 November 2024
4,209
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
38,709
11,225
Other debtors
-
0
21,291
38,709
32,516
THE BIONIC EYE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 5 -
5
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans and overdrafts
-
0
1,142
Trade creditors
11,487
9,276
Taxation and social security
32,194
1,924
Other creditors
80,228
15,841
123,909
28,183
6
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary Shares of £1 each
100
100
100
100
7
Related party transactions

The company has taken advantage of the exemptions permitted by FRS 102 section 1.AC.35 not to provide disclosures of transactions entered into with other wholly-owned members of the group.

 

At the balance sheet date, the Director owed the company £18,373 (2024: £1,796) in respect of interest-free loans.

 

 

2025-11-302024-12-01falsefalsefalse07 May 2026CCH SoftwareCCH Accounts Production 2025.300No description of principal activityA J Eio090530052024-12-012025-11-30090530052025-11-30090530052024-11-3009053005core:OtherPropertyPlantEquipment2025-11-3009053005core:OtherPropertyPlantEquipment2024-11-3009053005core:CurrentFinancialInstrumentscore:WithinOneYear2025-11-3009053005core:CurrentFinancialInstrumentscore:WithinOneYear2024-11-3009053005core:CurrentFinancialInstruments2025-11-3009053005core:CurrentFinancialInstruments2024-11-3009053005core:ShareCapital2025-11-3009053005core:ShareCapital2024-11-3009053005core:CapitalRedemptionReserve2025-11-3009053005core:CapitalRedemptionReserve2024-11-3009053005core:RetainedEarningsAccumulatedLosses2025-11-3009053005core:RetainedEarningsAccumulatedLosses2024-11-3009053005core:ShareCapitalOrdinaryShareClass12025-11-3009053005core:ShareCapitalOrdinaryShareClass12024-11-3009053005bus:Director12024-12-012025-11-3009053005core:PlantMachinery2024-12-012025-11-3009053005core:FurnitureFittings2024-12-012025-11-3009053005core:ComputerEquipment2024-12-012025-11-30090530052023-12-012024-11-3009053005core:OtherPropertyPlantEquipment2024-11-3009053005core:OtherPropertyPlantEquipment2024-12-012025-11-3009053005bus:OrdinaryShareClass12024-12-012025-11-3009053005bus:OrdinaryShareClass12025-11-3009053005bus:OrdinaryShareClass12024-11-3009053005bus:PrivateLimitedCompanyLtd2024-12-012025-11-3009053005bus:SmallCompaniesRegimeForAccounts2024-12-012025-11-3009053005bus:FRS1022024-12-012025-11-3009053005bus:AuditExemptWithAccountantsReport2024-12-012025-11-3009053005bus:FullAccounts2024-12-012025-11-30xbrli:purexbrli:sharesiso4217:GBP